HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: ACUITY Trial, ACC.07 Scientific Session and i2 Innovations Summit. Presentation Number: 2414-5 Patients with acute coronary syndromes who t
HARVEY WHITE, Auckland City Hospital, New Zealand
REFERENCE: ACUITY Trial, ACC.07 Scientific Session and i2 Innovations Summit. Presentation Number: 2414-5Patients with acute coronary syndromes who take bivalirudin have fewer major bleeding events and a lower incidence of late stent thrombosis compared with those who receive standard heparin therapy. This is the finding of one year results from the ACUITY study announced by Gregg Stone of Columbia University, New York during the American College of Cardiology annual meeting that took place in New Orleans. Sarah Maxwell askedHarvey Whiteat the Auckland City Hospital in New Zealand to comment about the ACUITY investigation.
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Never Too Old For Hypertension Treatment!
Nigel Beckett Nick Boon Nigel Beckett, Imperial College, London COMMENT: Nick Boon, British Cardiovascular Society, London Even very old patients benefit greatly if you treat their hypertension. This